Latest Lilly Research Laboratories Stories
Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators INDIANAPOLIS, Sept.
OXFORD, England and INDIANAPOLIS, July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development
Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects SAN FRANCISCO,
Lilly expects U.S.
Association of Strategic Alliance Professionals recognizes exemplary and enduring success of landmark strategic partnership PRINCETON, N.J.
INDIANAPOLIS, Feb. 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014. Jan M.
Deal Represents Positive Milestone for Alternative R&D Funding Strategy INDIANAPOLIS, Jan.
- The act of sweetening by admixture of some saccharine substance.